Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Clarke To Oversee Glaxo Consumer Division During Xenical Switch Bid

This article was originally published in The Tan Sheet

Executive Summary

Glaxo's plan to switch Xenical (orlistat 60 mg) to over-the-counter status for adults only "provides difficulties in the ultimate marketing," incoming Consumer Healthcare president John Clarke allowed
Advertisement

Related Content

Xenical Study Supports Proposed Nonprescription Dose, Glaxo Says
Xenical Study Supports Proposed Nonprescription Dose, Glaxo Says
Xenical Study Supports Proposed Nonprescription Dose, Glaxo Says
GSK Sees Big Opportunity In OTC Diet Aids: Xenical Switch NDA Filed
GSK Sees Big Opportunity In OTC Diet Aids: Xenical Switch NDA Filed
Block Acquisition Could Boost SmithKline International Sales By $560 Mil.

Topics

Advertisement
UsernamePublicRestriction

Register

PS098646

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel